Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Cannabis Regulation topic
No spam. Unsubscribe anytime.
Senate committee advances package to streamline Minnesota’s cannabis supply chain amid concerns about canopy limits
Summary
The Commerce Committee advanced a package of bills intended to merge separate medical and adult-use cannabis supply chains into a single system and to create a new MAC (macro) business license, while senators and tribal and patient advocates pressed for protections for medical patients, limits on canopy size, phased transitions and grandfathering for incumbents.
Senators in the Commerce and Consumer Protection Committee on March 24 advanced a set of bills aimed at streamlining Minnesota’s medical and adult-use cannabis markets while attempting to preserve patient access and local control.
Sen. Double, chief author of the package, said the bills would eliminate duplicative supply chains and allow businesses to share facilities, inventory and operations until the point of sale — preserving medical registry protections and requiring medical retailers to provide pharmacist or consultant oversight for patients. “This creates clarity, fairness and scalability across the market,” he said.
Nut graf: Supporters, including the Office of Cannabis Management (OCM), argued the changes would lower costs and increase patient access to non‑intoxicating medical products; opponents and some tribal representatives warned the proposals could concentrate market power if large canopy allowances go into effect too quickly.
Director Kabul of OCM told the committee the office worked extensively with stakeholders and that the reform package is intended to preserve access to high-need medical products while enabling a more efficient market. Kabul said the office estimates statewide canopy demand at roughly 1.5 to 2 million square feet and explained that combining supply chains reduces duplication because product only becomes medical at point of sale.
Tribal and small-business speakers urged a phased approach. Blake Johnson, representing a working group of tribes, said the tribes supported streamlining in principle but asked for a delayed phase-in and a gradual increase in canopy to prevent large incumbents from dominating the market. “We support streamlining, with emphasis on a two‑year delay,” Johnson said during testimony.
Committee members repeatedly pressed for assurances about market stability and investor expectations, asking whether existing license holders should be grandfathered and how canopy limits (options discussed included 30,000 and 45,000 square feet) would be phased in. Director Kabul outlined a proposal that begins with a lower canopy and allows staged increases over several years to reach higher limits only as the market matures.
The package also contains provisions to (a) clarify endorsement structures so the same activity is regulated consistently regardless of license type, (b) create a petition process to move micro businesses to larger license tiers, and (c) preserve certain medical‑only product protections and tax exemptions for patients.
The committee adopted several author amendments and laid some bills over or referred others to Finance for further review. Members asked OCM and stakeholders to continue conversations about grandfathering, transition timelines and data-driven assessments of market capacity before final floor action.
The committee laid SF 4541 (as amended) over for further consideration; related bills in the package were either laid over or forwarded to other committees for additional review. The committee did not take final floor action on the substantive licensing elements during the hearing.
